Effect of type 1 transforming growth factor-β on the level of aromatase cytochrome P-450 in human fetal hepatocytes

W. E. Rainey, M. T. Price, G. D. Means, B. R. Carr

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aromatase cytochrome P-450 (P-450(AROM)) is the enzyme in the steroidogenic pathway controlling the formation of oestrogens from 19 carbon steroid precursors. Aromatase is present in various tissues of the human fetus. The liver is second only to the placenta in the level of P-450(AROM) activity in the fetus. In this study we examined the effects of type 1 transforming growth factor-β (TGFβ) on P-450(AROM) expression in human fetal (HF) hepatocytes. The HF hepatocytes were dispersed into single cells which were placed into monolayer cell culture until confluent. Cells were then rinsed and treated in serum-free media with dibutyryl cyclic AMP (Bu2cAMP) for 72 h. Treatment with Bu2cAMP (2 mmol/l) caused a fivefold increase in aromatase activity in hepatocytes. The increase in aromatase activity apparently represented an increase in P-450(AROM) enzyme as determined by immunoblotting using an antibody directed against human placental aromatase. TGFβ blocked basal, as well as Bu2cAMP increases, in aromatase activity by over 50%. The effect of TGFβ was dose-dependent with maximal inhibition observed using 2-5 ng TGFβ/ml. Immunodetectable P-450(AROM) decreased in parallel with activity following TGFβ treatment. The mechanism of TGFβ action was not through increasing phosphodiesterase (PDE) breakdown of cAMP since inhibition of PDE had no effect on TGFβ action. Finally we examined the level of P-450(AROM) mRNA using competitive polymerase chain reaction amplification. Bu2cAMP increased mRNA levels of P-450(AROM) by 2.5-fold, while TGFβ inhibited this induction by 35%. The results of this investigation demonstrated that TGFβ is a potent regulator of P-450(AROM) expression in HF hepatocytes.

Original languageEnglish (US)
Pages (from-to)311-320
Number of pages10
JournalJournal of Endocrinology
Volume133
Issue number2
StatePublished - 1992

Fingerprint

Aromatase
Transforming Growth Factors
Cytochrome P-450 Enzyme System
Hepatocytes
Phosphoric Diester Hydrolases
Fetus
Bucladesine
Messenger RNA
Serum-Free Culture Media
Immunoblotting
Placenta
Estrogens
Carbon
Cell Culture Techniques
Steroids
Polymerase Chain Reaction
Antibodies
Liver

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effect of type 1 transforming growth factor-β on the level of aromatase cytochrome P-450 in human fetal hepatocytes. / Rainey, W. E.; Price, M. T.; Means, G. D.; Carr, B. R.

In: Journal of Endocrinology, Vol. 133, No. 2, 1992, p. 311-320.

Research output: Contribution to journalArticle

@article{47f25130eb9c4e7f9f5240dac8b8e9fa,
title = "Effect of type 1 transforming growth factor-β on the level of aromatase cytochrome P-450 in human fetal hepatocytes",
abstract = "Aromatase cytochrome P-450 (P-450(AROM)) is the enzyme in the steroidogenic pathway controlling the formation of oestrogens from 19 carbon steroid precursors. Aromatase is present in various tissues of the human fetus. The liver is second only to the placenta in the level of P-450(AROM) activity in the fetus. In this study we examined the effects of type 1 transforming growth factor-β (TGFβ) on P-450(AROM) expression in human fetal (HF) hepatocytes. The HF hepatocytes were dispersed into single cells which were placed into monolayer cell culture until confluent. Cells were then rinsed and treated in serum-free media with dibutyryl cyclic AMP (Bu2cAMP) for 72 h. Treatment with Bu2cAMP (2 mmol/l) caused a fivefold increase in aromatase activity in hepatocytes. The increase in aromatase activity apparently represented an increase in P-450(AROM) enzyme as determined by immunoblotting using an antibody directed against human placental aromatase. TGFβ blocked basal, as well as Bu2cAMP increases, in aromatase activity by over 50{\%}. The effect of TGFβ was dose-dependent with maximal inhibition observed using 2-5 ng TGFβ/ml. Immunodetectable P-450(AROM) decreased in parallel with activity following TGFβ treatment. The mechanism of TGFβ action was not through increasing phosphodiesterase (PDE) breakdown of cAMP since inhibition of PDE had no effect on TGFβ action. Finally we examined the level of P-450(AROM) mRNA using competitive polymerase chain reaction amplification. Bu2cAMP increased mRNA levels of P-450(AROM) by 2.5-fold, while TGFβ inhibited this induction by 35{\%}. The results of this investigation demonstrated that TGFβ is a potent regulator of P-450(AROM) expression in HF hepatocytes.",
author = "Rainey, {W. E.} and Price, {M. T.} and Means, {G. D.} and Carr, {B. R.}",
year = "1992",
language = "English (US)",
volume = "133",
pages = "311--320",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "2",

}

TY - JOUR

T1 - Effect of type 1 transforming growth factor-β on the level of aromatase cytochrome P-450 in human fetal hepatocytes

AU - Rainey, W. E.

AU - Price, M. T.

AU - Means, G. D.

AU - Carr, B. R.

PY - 1992

Y1 - 1992

N2 - Aromatase cytochrome P-450 (P-450(AROM)) is the enzyme in the steroidogenic pathway controlling the formation of oestrogens from 19 carbon steroid precursors. Aromatase is present in various tissues of the human fetus. The liver is second only to the placenta in the level of P-450(AROM) activity in the fetus. In this study we examined the effects of type 1 transforming growth factor-β (TGFβ) on P-450(AROM) expression in human fetal (HF) hepatocytes. The HF hepatocytes were dispersed into single cells which were placed into monolayer cell culture until confluent. Cells were then rinsed and treated in serum-free media with dibutyryl cyclic AMP (Bu2cAMP) for 72 h. Treatment with Bu2cAMP (2 mmol/l) caused a fivefold increase in aromatase activity in hepatocytes. The increase in aromatase activity apparently represented an increase in P-450(AROM) enzyme as determined by immunoblotting using an antibody directed against human placental aromatase. TGFβ blocked basal, as well as Bu2cAMP increases, in aromatase activity by over 50%. The effect of TGFβ was dose-dependent with maximal inhibition observed using 2-5 ng TGFβ/ml. Immunodetectable P-450(AROM) decreased in parallel with activity following TGFβ treatment. The mechanism of TGFβ action was not through increasing phosphodiesterase (PDE) breakdown of cAMP since inhibition of PDE had no effect on TGFβ action. Finally we examined the level of P-450(AROM) mRNA using competitive polymerase chain reaction amplification. Bu2cAMP increased mRNA levels of P-450(AROM) by 2.5-fold, while TGFβ inhibited this induction by 35%. The results of this investigation demonstrated that TGFβ is a potent regulator of P-450(AROM) expression in HF hepatocytes.

AB - Aromatase cytochrome P-450 (P-450(AROM)) is the enzyme in the steroidogenic pathway controlling the formation of oestrogens from 19 carbon steroid precursors. Aromatase is present in various tissues of the human fetus. The liver is second only to the placenta in the level of P-450(AROM) activity in the fetus. In this study we examined the effects of type 1 transforming growth factor-β (TGFβ) on P-450(AROM) expression in human fetal (HF) hepatocytes. The HF hepatocytes were dispersed into single cells which were placed into monolayer cell culture until confluent. Cells were then rinsed and treated in serum-free media with dibutyryl cyclic AMP (Bu2cAMP) for 72 h. Treatment with Bu2cAMP (2 mmol/l) caused a fivefold increase in aromatase activity in hepatocytes. The increase in aromatase activity apparently represented an increase in P-450(AROM) enzyme as determined by immunoblotting using an antibody directed against human placental aromatase. TGFβ blocked basal, as well as Bu2cAMP increases, in aromatase activity by over 50%. The effect of TGFβ was dose-dependent with maximal inhibition observed using 2-5 ng TGFβ/ml. Immunodetectable P-450(AROM) decreased in parallel with activity following TGFβ treatment. The mechanism of TGFβ action was not through increasing phosphodiesterase (PDE) breakdown of cAMP since inhibition of PDE had no effect on TGFβ action. Finally we examined the level of P-450(AROM) mRNA using competitive polymerase chain reaction amplification. Bu2cAMP increased mRNA levels of P-450(AROM) by 2.5-fold, while TGFβ inhibited this induction by 35%. The results of this investigation demonstrated that TGFβ is a potent regulator of P-450(AROM) expression in HF hepatocytes.

UR - http://www.scopus.com/inward/record.url?scp=0026507817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026507817&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 311

EP - 320

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 2

ER -